UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 87

Sortiert nach

Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer

Internal Medicine, 2018/05/01, Vol.57(9), pp.1269-1272

2018

Link zum Volltext

Verfügbarkeit prüfen

Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS)

International journal of clinical oncology, 2023-01, Vol.28 (1), p.79-88

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

BMC cancer, 2018-10, Vol.18 (1), p.946-946, Article 946

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

BMC cancer, 2020-02, Vol.20 (1), p.115-115, Article 115

2020

Link zum Volltext

Verfügbarkeit prüfen

The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease

Japanese journal of clinical oncology, 2018-01, Vol.48 (1), p.89-93

2018

Link zum Volltext

Verfügbarkeit prüfen

Reply to C.-H. Chang et al

Journal of clinical oncology, 2017-04, Vol.35 (12), p.1375-1376

Urata, Yoshiko

2017

Link zum Volltext

Verfügbarkeit prüfen

Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing

Lung cancer (Amsterdam, Netherlands), 2019-02, Vol.128, p.20-25

2019

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients

Respiratory investigation, 2020-07, Vol.58 (4), p.269-274

2020

Link zum Volltext

Verfügbarkeit prüfen

Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study

Respiratory investigation, 2016-09, Vol.54 (5), p.334-340

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

Journal of clinical oncology, 2016-09, Vol.34 (27), p.3248-3257

2016

Link zum Volltext

Verfügbarkeit prüfen

Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase

Kobe journal of the medical sciences, 2005, Vol.51 (1-2), p.17-27

2005

Link zum Volltext

Verfügbarkeit prüfen

I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?

Gan to kagaku ryoho, 2015-08, Vol.42 (8), p.931

2015

Link zum Volltext

Verfügbarkeit prüfen

A retrospective study of effectiveness and safety of Nivolmab for advanced or recurrent NSCLC harboring EGFR mutation

Annals of oncology, 2017-10, Vol.28 Suppl 9, p.ix99-ix100

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of anti-PD-1/PD-L1 antibody after discontinuation of antibody due to non-progressive disease in NSCLC Patients

Annals of oncology, 2017-10, Vol.28 Suppl 9, p.ix85

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations

Lung cancer (Amsterdam, Netherlands), 2018-10, Vol.124, p.65-70

2018

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212)

Anticancer research, 2015-07, Vol.35 (7), p.3885-3891

2015

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)

Lung cancer (Amsterdam, Netherlands), 2015-08, Vol.89 (2), p.146-153

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor ( EGFR ) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)

Lung cancer (Amsterdam, Netherlands), 2015-02, Vol.87 (2), p.136-140

2015

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open- label phase 2 study (CLEAR)

Translational lung cancer research, 2021-07, Vol.10 (7), p.3059-3070

2021

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Study of Pemetrexed in Ps 2 Patients with Advanced Egfr Wild-Type Non-Squamous Non-Small Cell Lung Cancer

Annals of oncology, 2014-10, Vol.25, p.v68

2014

Link zum Volltext

Verfügbarkeit prüfen

A phase II open-label single-arm study of vandetanib in patients with advanced RET -rearranged non-small cell lung cancer (NSCLC): Luret study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9012-9012

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)

Cancer chemotherapy and pharmacology, 2015-06, Vol.75 (6), p.1267-1272

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of S‐1 and carboplatin plus bevacizumab followed by maintenance S‐1 and bevacizumab for chemotherapy‐naive patients with advanced nonsquamous non–small cell lung cancer

Cancer, 2013-06, Vol.119 (12), p.2275-2281

2013

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8056-8056

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 87

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(82)

Publikationsform

Sprache

Englisch
(73)
Japanisch
(26)

Erscheinungsjahr

n.n

Thema

Humans
(32)
Science & Technology
(29)
Life Sciences & Biomedicine
(26)
Female
(22)
Male
(21)
Aged
(19)
Oncology
(19)
Middle Aged
(18)
Lung Neoplasms - Drug Therapy
(16)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(14)
Adult
(11)
Non-Small Cell Lung Cancer
(10)
Lung Neoplasms - Mortality
(8)
Respiratory System
(8)
Treatment Outcome
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Carcinoma, Non-Small-Cell Lung - Mortality
(7)
Tumors
(7)
Biological And Medical Sciences
(6)
Cancer Research
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer

Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease

Reply to C.-H. Chang et al

Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing

The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients

Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase

I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?

Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial

A retrospective study of effectiveness and safety of Nivolmab for advanced or recurrent NSCLC harboring EGFR mutation

Efficacy of anti-PD-1/PD-L1 antibody after discontinuation of antibody due to non-progressive disease in NSCLC Patients

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations

Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212)

A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)

A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor ( EGFR ) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)

Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open- label phase 2 study (CLEAR)

A Phase II Study of Pemetrexed in Ps 2 Patients with Advanced Egfr Wild-Type Non-Squamous Non-Small Cell Lung Cancer

A phase II open-label single-arm study of vandetanib in patients with advanced RET -rearranged non-small cell lung cancer (NSCLC): Luret study

A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)

Phase 2 study of S‐1 and carboplatin plus bevacizumab followed by maintenance S‐1 and bevacizumab for chemotherapy‐naive patients with advanced nonsquamous non–small cell lung cancer

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial

Suchergebnisse filtern